Newly Activated Studies

These studies have recently activated. More information can be found on [CTSU].

- **NRG-GU012**: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

- **A032101**: A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DR

- **S1900F**: A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)

Research Base Meetings

2022 NCORP Annual Meeting
NCORP Annual Meeting

August 25–26, 2022

Virtual Registration Now Open!

Registration must be completed by August 18, 2022

The Cancer Letter

MONICA BERTAGNOLI, FIRST WOMAN AND FIRST CLINICAL TRIALS GROUP CHAIR TO DIRECT THE NATIONAL CANCER INSTITUTE

Monica M. Bertagnolli, a professor of surgery at Harvard Medical School, stands poised to become the first woman and the first chief of a clinical trials group to be named director of the National Cancer Institute.

Registration Now Open!

Registration must be completed by August 18, 2022

The Cancer Letter

ALL COLORECTAL CANCER PATIENTS REQUIRE CERVICAL TESTING AT DIAGNOSIS AND SOMATIC TESTING AT ADVANCED DISEASE DIAGNOSIS

Technological advances are transforming our understanding of cancer, accelerating development of new treatment approaches.

July 22, 2022

July 15, 2022
Accruals & Biospecimens–Special Entries

GY3 June 2022 Accruals
By Affiliate Site

- SMC: 26 (7 Accruals, 5 Biospecimens & Special Entries)
- BSSF: 5 (10 Accruals, 3 Biospecimens & Special Entries)
- AnMed: 3 (1 Bio-specimens & Special Entries)
- UC NCORP: 26 (15 Accruals, 10 Biospecimens & Special Entries)

*TMIST Only* • **Accruals** • **Biospecimens & Special Entries**
Under-Represented Populations

Underrepresented Populations

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AYA (15-39 yrs.)</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>6</td>
<td>5</td>
<td>2</td>
<td>15</td>
<td>5</td>
<td>5</td>
<td>4</td>
<td>4%</td>
<td>21.43%</td>
</tr>
<tr>
<td>Older Adults (&gt;65 yrs.)</td>
<td>24</td>
<td>17</td>
<td>17</td>
<td>22</td>
<td>15</td>
<td>10</td>
<td>21</td>
<td>22</td>
<td>8</td>
<td>30</td>
<td>17</td>
<td>55%</td>
<td>42%</td>
</tr>
<tr>
<td>African American</td>
<td>11</td>
<td>14</td>
<td>13</td>
<td>7</td>
<td>7</td>
<td>5</td>
<td>13</td>
<td>13</td>
<td>6</td>
<td>13</td>
<td>13</td>
<td>17.6%</td>
<td>21%</td>
</tr>
<tr>
<td>Other Minorities</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>0.4%</td>
<td>1.8%</td>
</tr>
<tr>
<td>Hispanic</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1%</td>
<td>2.2%</td>
</tr>
<tr>
<td>Rural</td>
<td>21</td>
<td>27</td>
<td>20</td>
<td>11</td>
<td>9</td>
<td>8</td>
<td>18</td>
<td>18</td>
<td>11</td>
<td>10</td>
<td>16</td>
<td>35%</td>
<td>31%</td>
</tr>
</tbody>
</table>

CCDR Corner
July is Sarcoma Cancer Awareness Month. This annual initiative strives to raise awareness about what is considered the "forgotten cancer" and to encourage research and drug development surrounding this rare disease. The two main types of sarcomas are soft tissue sarcoma and bone sarcoma, specifically osteosarcoma. Despite the limitations of sarcoma epidemiologic analyses due to the disease's heterogeneity and rarity, evidence-based findings from the...
Surveillance, Epidemiology, and End Results (SEER) program and the National Cancer Database (NCDB) identified racial disparities in sarcoma-specific outcomes and survival. For example, the large databases reveal that African Americans had the highest five-year risk of death and were less likely to receive adjuvant radiation with surgery than white, Hispanic, and Asian patients (Lazarides, Visgauss, Nussbaum, et al., 2018). Additionally, a 2021 study published in Surgical Oncology found that socioeconomic factors are associated with amputation for extremity bone sarcomas. For example, those with an annual household income lower than $75k yearly treated in public hospitals with lower extremity sarcoma were at greater risk for amputation than those with an annual income of $125k yearly with upper extremity sarcoma. Also, the data from the Surgical Oncology study indicated patients with higher annual income and upper extremity sarcomas had limb surgery salvage surgery (Houdek et al., 2021). With the differences in the treatment and survival of sarcoma patients, future studies are essential to ensure adequate access to effective treatment for all patients regardless of race, ethnicity, geographic location, and socioeconomic status. In addition, improvement in cancer treatment outcomes requires complex diagnostic and treatment procedures given by multidisciplinary teams, emphasizing the need for community partnerships, especially for rare tumors, such as sarcomas (Biermann, Chugh, Siegel, et al., 2015), (Diessner, Weigel, Murugan, et al., 2020).

To learn more about global initiatives regarding disparities in sarcoma cancer, follow the link below!

[Disparities in Cancer Care](#)

**QA with Kristen**

**Upcoming Audit**

**NRG Audit**

August 17–19, 22–23

Do you have any staff you would like highlighted in The Connector? Please submit it by the 15th of the month to Alaina: akennedy@srhs.com

Connect with us on LinkedIn! [@UpstateCarolinaNCORP](#)

Click here to visit our website

**Administrator**

Kamara Mertz-Rivera, MA, CCRC

Email: UpstateNCORP@srhs.com

Phone: 864-560-6104

**eRegulatory Systems**

Laura Bailey, BS, CCRP

Email: UpstateNCORPRegulatory@srhs.com

**Grant Manager**

Alex Akkary, MBA

Email: UpstateNCORPFinance@srhs.com

Phone: 864-560-6967

**Quality Assurance**

Kristen Ford, BSN MSN

Email: UpstateNCORPQA@srhs.com